Fosfomycin Duration for ESBL Infections
For uncomplicated cystitis caused by ESBL-producing organisms, use a single 3-gram oral dose of fosfomycin; for complicated urinary tract infections without septic shock, use oral fosfomycin 3 grams every 48-72 hours for 2-6 weeks depending on infection severity and clinical response.
Uncomplicated Cystitis (Simple Bladder Infection)
A single 3-gram oral dose is the standard regimen 1. This applies even when the causative organism is ESBL-producing E. coli or K. pneumoniae. The 2011 IDSA/ESCMID guidelines note that fosfomycin demonstrates in vitro activity against ESBL-producing gram-negative rods, with observational studies supporting clinical efficacy 1.
- Clinical cure rates of 83-91% have been documented 2
- Microbiological cure rates around 80% 1
- The single-dose regimen maintains urinary concentrations >100 mcg/mL for 26 hours 3
The 2022 Taiwan guidelines specifically recommend a single 3-gram oral dose for uncomplicated UTIs due to VRE (which shares similar resistance patterns), supporting this approach for ESBL organisms 4.
Complicated Urinary Tract Infections (cUTI)
For complicated UTIs caused by ESBL-producing organisms, the duration extends significantly beyond a single dose:
Acute Complicated UTI/Pyelonephritis
- Oral fosfomycin 3 grams every 48 hours for 2.5 weeks (mean duration) was effective in achieving clinical and microbiological cure in acute UTI cases 5
- The 2022 ESCMID guidelines note that IV fosfomycin showed no significant differences compared to carbapenems for cUTI caused by ESBL-producing organisms, including patients with bacteremia (but excluding septic shock) 6
Chronic Bacterial Prostatitis
- Oral fosfomycin 3 grams every 24-48 hours for 5.5 weeks (mean duration) achieved clinical and microbiological recovery in 16/17 cases 5
- This extended duration is necessary due to poor prostatic penetration and biofilm formation
Step-Down Therapy After IV Antibiotics
- Oral fosfomycin 3 grams every 24-72 hours can be used as step-down therapy after initial IV treatment 7, 8
- A 2022 retrospective study showed comparable outcomes between fosfomycin and ertapenem for outpatient cUTI treatment, with fosfomycin given at varying intervals (daily, every other day, every third day) 8
- Duration should be guided by clinical response and imaging follow-up
Key Clinical Considerations
Important caveats:
- Avoid in septic shock: The 2022 ESCMID guidelines specifically exclude patients with septic shock from fosfomycin recommendations 6
- Cardiac risk: The FOREST trial documented heart failure in 8.6% of patients receiving IV fosfomycin versus 1% with meropenem; use cautiously in patients at risk for heart failure 6
- Susceptibility testing: While 96.8% of ESBL-producing E. coli and 81.3% of ESBL-producing K. pneumoniae are susceptible to fosfomycin 9, testing is not routinely performed in many laboratories 1
- Lower bacterial eradication: Fosfomycin has lower microbiological efficacy (80%) compared to other first-line agents (>90%), though clinical efficacy remains comparable 1
Dosing specifics:
- The standard oral dose is 3 grams of fosfomycin trometamol 3
- Can be taken without regard to food, though absorption is slightly reduced with high-fat meals 3
- Urinary concentrations remain therapeutic (>100 mcg/mL) for 26 hours after a single dose 3
Resistance monitoring: Recent data from 2025 shows fosfomycin resistance remains low (5%) among ESBL-producing E. coli in some regions 10, though continuous surveillance is needed given increasing use.